Boston: Alzheimer's disease has now become a challenge for the whole world for which an unconventional way of treatment has emerged. Scientists believe that light and sound can reduce the severity of this painful disease and have many benefits.
According to a study published in the Public Library of Science One, the therapy has been shown to be useful in early experiments. However, it has only been tested on a few patients. Massachusetts Institute of Technology (MIT) professor Lai Hoe Tsai and his colleagues have researched it for seven years. Defective proteins in the brain cause Alzheimer's. Experts put special lights on the mice and played some sounds, then the harmful proteins started to decrease. Continued observation found that 40 Hz light had magical properties and was found to be suitable for healing.
After the rats, the therapy was tested on 43 patients at the hospital, which they called Gamma EN Training Using Sensory Simulation (JENS), meaning they were exposed to lights and sounds for short periods of time while EEGs recorded brain notes. It was done. But it included healthy people as well as Alzheimer's and epilepsy patients. It has been found that many parts of the brain synchronize with a frequency of 40 Hz.
Further research revealed that light and sound of this frequency is very important because it is not only activating the sensory areas, but also the amygdala, hippocampus and insula.
Another experiment involved 15 people with early-stage Alzheimer's. They were given a device and told to take it home and use it for an hour a day. The device consisted of a 40 Hz light-emitting LED and a sound-emitting iPad tablet and speaker. Patients watched the video on an iPad while the LED lights were illuminated by jhumkas. After three months, the subjects who heard the 40 Hz light and sound showed a clear difference in their disease. They were then further tested with memory tests and other items.
Such patients began to sleep a little more contented and restfully, even their daily performance began to improve. In the next phase, it will be tested on a larger number of patients.
